Molecular mechanisms of matrix metalloproteinase (MT-MMP) induction of cancer cell migration and metastasis  by Zucker, Stanley & Cao, Jian
PMA-induced, K-ras- and Src-induced gene expression. New data
will be presented in this lecture showing that the newly character-
ized tumor suppressor Pdcd4 suppresses u-PAR gene expression,
this again in part being mediated by Sp3 bound to the 152/
135 motif.
Furthermore, the lecture will focus on the differential binding
of transcription factors to both u-PAR promoter elements in vivo,
having been investigated in a large series of resected tumor and
normal tissue of colorectal and gastric cancer patients. We will
demonstrate that, depending on the transcription factor and cis-
element, patient subgroups of different size can be selected in
which transactivation via these promoter elements might be
tumor-tissue-specific, suggesting subgroups for tumor-selective
targeting. Also, the lecture will outline that different u-PAR-pro-
moter motifs may be of different tumor-specificity in vivo. We will
also suggest patient subgroups in which a synergistic regulation
of u-PAR gene expression in resected tissues via both promoter
elements can be postulated. Finally, first data on a clinical-prog-
nostic relevance of differential transcription factor binding to
specific u-PAR-promoter motifs will be shown, suggesting the
binding of, for example, Sp1, and transcription factor combina-
tions out of Sp1/AP-2 and AP-1-binding as new and independent
predictors of disease-specific survival. A first molecularly
extended staging model will be presented from these data. Poten-
tial conclusions for a more target-oriented patient selection and
therapy out of transcriptional and oncogeneic regulators of the
uPA-R gene will be discussed.
doi:10.1016/j.ejcsup.2006.04.011
S11. uPA AND PAI-1: CLINICALLY AND TECHNICALLY
VALIDATED PROGNOSTIC MARKERS IN BREAST CANCER
M.J. Duffy. St Vincent’s University Hospital, Dublin, Ireland.
For optimum management of patients with cancer, accurate
prognostic factors are required. The primary determinant of out-
come in patients with malignancy is cancer progression, espe-
cially the formation of distant metastases. Based on data from
model systems, urokinase plasminogen activator (uPA) is one of
the critical mediators of cancer progression. uPA appears to
mediate progression via multiple mechanisms including remod-
elling of the extracellular matrix, enhancing cell proliferation
and migration and modulating cell adhesion. PAI-1, although
originally identified as an inhibitor of uPA, is also causally
involved in cancer progression. Consistent with their roles in
cancer progression, multiple independent studies have shown
that elevated levels of uPA and PAI-1 predict poor prognosis in
patients in breast cancer. The prognostic impact of uPA and
PAI-1 is potent (e.g., RR > 2.0), independent of standard prognostic
factors and found in both lymph node-negative and lymph node-
positive disease. Importantly, the prognostic impact of uPA/PAI-1
has been validated in both a randomized prospective trial and a
pooled analysis, i.e., in 2 level I evidence studies. In addition to
clinical validation, specific ELISA for uPA and PAI-1 have under-
gone technical validation including validation in an external
quality assurance program. uPA and PAI-1 are thus now ready
for clinical application, especially in the identification of newly
diagnosed breast cancer patients that may be able to avoid hav-
ing to receive adjuvant chemotherapy.
doi:10.1016/j.ejcsup.2006.04.012
S12. EXPRESSION OF MARKERS OF INVASION AND
PROGRESSION – COMPARING MOLECULAR DETERMINANTS
WITH PHENOTYPES
Rainer Grobholz. Department of Pathology, University Hospital
Mannheim, Ruprecht-Karls-University Heidelberg, Theodor-Kuzuer-
Ufer 1-3, D-68167 Mannheim, Germany.
Cancer cells usually have a distinct morphological and genetic
profile that allows to determine between reactive, premalignant
and malignant lesions. In some tumor entities, however, morpho-
logical and expression profiles do not necessarily reflect the true
nature of the putative lesion. Molecular biological advances could
further clarify the biological potential in some tumor entities, in
others however, morphological and topographical criteria are still
crucial, since no evident typical molecular profiles could be deter-
mined so far.
Prostate cancer is a prominent example of cancer where exo-
crine and neuroendocrine (NE) tumor cells can occur within the
same tumor. The role of these NE cells is still under debate, even
the question of its neoplastic nature and its biological signifi-
cance. Since in these NE cells no proliferation could be demon-
strated so far, NE tumor cells in prostate cancer are regarded as
post-mitotic and their significance has been regarded as ‘low’.
The interesting question is, therefore, whether a post-mitotic
cancer cell still deserves the attribute ‘‘cancer cell’’ and what
are its biological functions in the cancerous orchestration.
Although molecular and clinical data seem to give evidence that
NE tumor cells are the result of a transdifferentiation process
and possess a prognostic significance, their final role in vivo is
not yet completely understood.
doi:10.1016/j.ejcsup.2006.04.013
S13. MOLECULAR MECHANISMS OF MATRIX
METALLOPROTEINASE (MT-MMP) INDUCTION OF CANCER
CELL MIGRATION AND METASTASIS
Stanley Zucker, Jian Cao. Stony Brook University, Stony Brook, NY
11794, United States; Veterans Affairs Medical Center, Northport, NY
11768, United States.
Matrix metalloproteinases (MMPs) are important in cancer dis-
semination by virtue of degradation of extracellular matrix, as
well as diverse effects on cell growth, apoptosis, migration,
and angiogenesis. Negative results from clinical drug trials of
MMP inhibitors in advanced cancers has refocused attention
on the role of MMPs in early cancer development. Experimental
and clinical evidence suggests that membrane type 1-matrix
metalloproteinase (MT1-MMP) may serve as a master regulator
of cancer progression. The mechanism underlying this process
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remains to be defined. Epithelial-to-mesenchymal transition
(EMT) has emerged as a critical step in the conversion of early
stage to aggressive cancer. Employing our previously established
stable human cancer cell lines {prostate (LNCaP), breast (MCF-7)
and fibrosarcoma (HT1080) cells} over expressing MT1-MMP-GFP
(MT1-GFP) as well as GFP expressing control cells (Thromb Hae-
most 93:770–8; 2005), we examined the role of MT1-MMP in pro-
moting EMT. Expression of MT1-MMP in all three cell lines
promoted cell proliferation in 3 dimensional (3D) cultures, but
not in 2D cultures. Enzymatic activity of MT1-MMP is required
for enhanced cell proliferation suggesting that cellular degrada-
tion of surrounding collagen is a prerequisite. GFP-expressing
control LNCaP and MCF-7 cells cultivated in 3D type I collagen
gels gradually formed spherical aggregates, whereas cells
expressing MT1-GFP displayed a scattered growth pattern.
MT1-MMP-induced cell scattering was abrogated by targeted
inhibition of either the catalytic domain (TIMP-2) or the hemo-
pexin domain (recombinant PEX) domain of MT1-MMP, indicat-
ing a specific role for each domain in cell scattering. Abrogation
of MT1-MMP-induced phenotypic changes (fibroblast-like mor-
phology and cell scattering) was reversible upon withdrawal of
inhibitors. MT1-MMP transfected LNCaP and MCF-7 cells also
degraded the cell–cell adherins junction molecule, E-cadherin.
In contrast to epithelial carcinoma (LNCaP, MCF-7), non trans-
fected HT1080 cells, which are mesenchymal in origin, dis-
played a scattered growth pattern in 3D collagen gels.
Transfection of HT1080 cells with MT1-MMP or treatment with
high dose TIMP-2, did not alter the scattered growth pattern
of HT1080 cells. These results are consistent with experiments
demonstrating that mesenchymal-amoeboid cell invasion is
independent of MMP activity (Wolf, K., et al. J. Cell Biol. 160:
267–77; 2003). We hypothesize that MT1-MMP degradation of
E-cadherin and collagen induce signal transduction pathways
leading to mesenchymal-associated morphologic changes and
promoting cancer cell migration and proliferation in 3D colla-
gen gels, thus recapitulating EMT. The central role of MT1-
MMP in epithelial cancer progression provides a stimulus for
development of specific inhibitors as treatment of early stage
cancer.
doi:10.1016/j.ejcsup.2006.04.014
S14. CROSS-ANALYSIS OF GENE AND miRNA EXPRESSION IN
HEREDO-FAMILIAL BREAST CANCERS
Marco A. Pierotti. Department of Experimental Oncology and Labs.,
Istituto Nazionale per lo studio e la Cura dei Tumori, Milan,
Italy; Cancer Genetic Unit at the FIRC Institute of Molecular Oncology
Foundation (IFOM Foundation), Milan, Italy.
Five to ten percent of all breast carcinomas originate from a
hereditary predisposition. Some of them have been associated
to mutations in the BRCA1 and BRCA2 susceptibility genes.
However, a large number of hereditary breast cancer cases are
not accounted by mutations in these two genes and are
believed to be due to as yet unidentified breast cancer predispo-
sition genes (BRCAX). Despite intensive effort, their identifica-
tion has been so far unsuccessful, presumably because of
genetic heterogeneity, low penetrance, or recessive/polygenic
mechanisms.
We have performed a comprehensive transcriptional profiling
analysis on a group of tumor specimens from BRCA patients with
the aim to find if the different genetic condition can distinguish
BRCA1, BRCA2 and BRCAX cases and is able to explain the heter-
ogeneity of BRCAX families. Moreover, we have integrated mRNA
and MiRNA analyses on the same cases to identify MiRNA depen-
dent mechanisms involved in hereditary breast cancer. We have
analyzed 50 familial breast cancer cases consisting in 18 samples
from patients characterized by carrying germ-line mutations of
BRCA1 gene, 11 samples with BRCA2 mutations and 20 samples
from BRCAX patients, respectively. As a control, 13 tumors from
patients with no family history of breast cancer were similarly
analyzed.
Since microarray studies showed that the main clusteriza-
tion in terms of gene expression profiles of breast cancers fol-
lows the status ER+ (estrogen receptor positive) and
ER (estrogen receptor negative), we applied a linear model that
adjusted for ER status the sample analysis. After the adjust-
ment, class comparison studies show that only BRCA1 samples
exhibited a significant number of differentially expressed genes
compared to any of the other hereditary or non-hereditary
groups of samples.
Interestingly, BRCAX cases cluster into two distinct sub-
groups, one mixed up to BRCA2 and sporadic cases, the other clo-
ser to BRCA1 samples, and containing only BRCAX cases. The dis-
tinct biological identity of the two sub-groups is further
supported by the fact that the same bipartition occurs when we
used the 6 genes common between our and Hedenfalk et al.’s
(PNAS, 100: 2532–7; 2003) classifier which defines BRCAX sub-
groups. Clinical characteristics of the tumors show that those
belonging to the group containing only BRCAX cases are similar
to BRCA1 tumors. Samples mixed to BRCA2 and sporadic cases
are more heterogeneous, suggesting a possible involvement of
low penetrance genes.
Analysis of the same cases by miRNA expression profile on an
array containing 245 miRNA from human and mouse genome
highlighted that miRNA deregulation is a frequent event in spo-
radic breast cancer and distinguishes it from the heredo-familial
cases. It is also worth noting that MiRNA analysis confirmed the
existence of the two BRCAX sub-groups.
We are now integrating gene expression and miRNA data to
identify the targets of the miRNAs found as differentially
expressed in the groups in analysis.
The work of the authors is supported by a grant of the Italian
Association for Cancer Research (AIRC).
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S15. USE OF SPECIALIZED ARRAYS FOR THE DIAGNOSIS OF
PANCREATIC TUMOURS
Thomas M. Gress. Philipps University Marburg, Germany.
DNA array technology holds great promises for the improvement
of diagnostic procedures in many medical fields. We demon-
strate that expression profiling analyses of FNAB samples using
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